{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:24:54Z","timestamp":1789017894119,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"European Union\u2019s Horizon Europe Research and Innovation Actions","award":["European Union\u2019s Horizon Europe Research"],"award-info":[{"award-number":["European Union\u2019s Horizon Europe Research"]}]},{"name":"European Union\u2019s Horizon Europe Research and Innovation Actions","award":["Innovation Actions under grant no. 101095479 (More-EUROPA)"],"award-info":[{"award-number":["Innovation Actions under grant no. 101095479 (More-EUROPA)"]}]},{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40259-025-00737-x","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:58:36Z","timestamp":1756223916000},"page":"927-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5648-2800","authenticated-orcid":false,"given":"Diogo","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mandslay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-3180","authenticated-orcid":false,"given":"Peter G. M.","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-0955","authenticated-orcid":false,"given":"Bruno","family":"Sepodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-9993","authenticated-orcid":false,"given":"Carla","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"737_CR1","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.healthpol.2022.10.007","volume":"126","author":"L Aguilera-Cobos","year":"2022","unstructured":"Aguilera-Cobos L, Rosario-Lozano MP, Ponce-Polo A, Blasco-Amaro JA, Epstein D. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: umbrella review. Health Policy. 2022;126:1248\u201355. https:\/\/doi.org\/10.1016\/j.healthpol.2022.10.007.","journal-title":"Health Policy"},{"key":"737_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jcyt.2023.06.005","volume":"25","author":"KLG Gomes","year":"2023","unstructured":"Gomes KLG, da Silva RE, da Silva JB, Bosio CGP, Novaes MRCG. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan. Cytotherapy. 2023;25:1113\u201323. https:\/\/doi.org\/10.1016\/j.jcyt.2023.06.005.","journal-title":"Cytotherapy"},{"key":"737_CR3","unstructured":"European Parliament and Council. Regulation (EC) no. 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and regulation (EC) no. 726\/2004 (Text with EEA relevance). 2007. https:\/\/eur-lex.europa.eu\/eli\/reg\/2007\/1394\/oj\/eng. Accessed 14 Feb 2025."},{"key":"737_CR4","unstructured":"European Medicines Agency. PRIME: priority medicines n.d. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines. Accessed 14 Feb 2025."},{"key":"737_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.757647","author":"M Pizevska","year":"2022","unstructured":"Pizevska M, Kaeda J, Fritsche E, Elazaly H, Reinke P, Amini L. Advanced therapy medicinal products\u2019 translation in Europe: a developers\u2019 perspective. Front Med (Lausanne). 2022. https:\/\/doi.org\/10.3389\/fmed.2022.757647.","journal-title":"Front Med (Lausanne)"},{"key":"737_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cpt.2462","volume":"111","author":"SM Eskola","year":"2022","unstructured":"Eskola SM, Leufkens HGM, Bate A, De Bruin ML, Gardarsdottir H. Use of real-world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018\u20132019. Clin Pharmacol Ther. 2022;111:310\u201320. https:\/\/doi.org\/10.1002\/cpt.2462.","journal-title":"Clin Pharmacol Ther"},{"key":"737_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023;29:49\u201358. https:\/\/doi.org\/10.1038\/s41591-022-02160-z.","journal-title":"Nat Med"},{"key":"737_CR8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.drudis.2018.03.008","volume":"23","author":"S de Wilde","year":"2018","unstructured":"de Wilde S, Coppens DGM, Hoekman J, de Bruin ML, Leufkens HGM, Guchelaar HJ, et al. Eu decision-making for marketing authorization of advanced therapy medicinal products: a case study. Drug Discov Today. 2018;23:1328\u201333. https:\/\/doi.org\/10.1016\/j.drudis.2018.03.008.","journal-title":"Drug Discov Today"},{"key":"737_CR9","unstructured":"European Medicines Agency. Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products. 2018. https:\/\/www.ema.europa.eu\/en\/guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-scientific-guideline. Accessed 14 Feb 2025."},{"key":"737_CR10","unstructured":"European Medicines Agency. European Medicines Agency post-authorisation procedural advice for users of the centralised procedure 2009. https:\/\/www.ema.europa.eu\/en\/pharmacovigilance-post-authorisation\/post-authorisation-measures-questions-and-answers. Accessed 14 Feb 2025."},{"key":"737_CR11","doi-asserted-by":"publisher","unstructured":"Rivetti di Val Cervo P, Alessi E, Lastella M, La Greca A, Trotta F. Advanced therapy medicinal products: availability, access and expenditure in Italy. BioDrugs 2024. https:\/\/doi.org\/10.1007\/s40259-024-00683-0.","DOI":"10.1007\/s40259-024-00683-0"},{"key":"737_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.924648","author":"CJ Jonker","year":"2022","unstructured":"Jonker CJ, Bakker E, Kurz X, Plueschke K. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.924648.","journal-title":"Front Pharmacol"},{"key":"737_CR13","unstructured":"European Medicines Agency. Patient registries n.d. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/patient-registries. Accessed 14 Feb 2025."},{"key":"737_CR14","unstructured":"European Medicines Agency. Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence\u2014scientific guideline. 2024. https:\/\/www.ema.europa.eu\/en\/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-scientific-guideline. Accessed 12 Feb 2025."},{"key":"737_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/cpt.1414","volume":"106","author":"CA Olmo","year":"2019","unstructured":"Olmo CA, McGettigan P, Kurz X. Barriers and opportunities for use of patient registries in medicines regulation. Clin Pharmacol Ther. 2019;106:39\u201342. https:\/\/doi.org\/10.1002\/cpt.1414.","journal-title":"Clin Pharmacol Ther"},{"key":"737_CR16","unstructured":"European Medicines Agency. Guideline on registry-based studies 2021. https:\/\/www.ema.europa.eu\/en\/guideline-registry-based-studies-scientific-guideline. Accessed 29 Feb 2025."},{"key":"737_CR17","unstructured":"European Medicines Agency. Download medicine data n.d. https:\/\/www.ema.europa.eu\/en\/medicines\/download-medicine-data. Accessed 3 Jan 2025."},{"key":"737_CR18","unstructured":"European Medicines Agency. Legal framework: Pharmacovigilance n.d. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/pharmacovigilance-overview\/legal-framework-pharmacovigilance. Accessed 12 Feb 2025."},{"key":"737_CR19","unstructured":"European Medicines Agency. HMA-EMA Catalogue of RWD studies n.d. https:\/\/catalogues.ema.europa.eu\/catalogue-rwd-studies. Accessed 3 Mar 2025."},{"key":"737_CR20","unstructured":"National Library of Medicine. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/. Accessed 3 Mar 2025."},{"key":"737_CR21","unstructured":"European Medicines Agency. Qualification of novel methodologies for drug development: guidance to applicants. 2014. https:\/\/www.ema.europa.eu\/en\/qualification-novel-methodologies-medicine-development. Accessed 12 Feb 2025."},{"key":"737_CR22","unstructured":"EUnetHTA. REQueST\u00ae Tool and its vision paper n.d. https:\/\/www.eunethta.eu\/request-tool-and-its-vision-paper\/. Accessed 13 Jan 2025."},{"key":"737_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3410","author":"D Mandslay","year":"2024","unstructured":"Mandslay D, Almeida D, Marques A, Rocha J, Drafi F, Sepodes B, et al. Comparative analysis of post-authorization measures for advanced medicinal products authorized in the European Union and in the United States of America between 2009 and 2023. Clin Pharmacol Ther. 2024. https:\/\/doi.org\/10.1002\/cpt.3410.","journal-title":"Clin Pharmacol Ther"},{"key":"737_CR24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s11606-014-2881-2","volume":"29","author":"AR Pariser","year":"2014","unstructured":"Pariser AR, Gahl WA. Important role of translational science in rare disease innovation, discovery, and drug development. J Gen Intern Med. 2014;29:804\u20137. https:\/\/doi.org\/10.1007\/s11606-014-2881-2.","journal-title":"J Gen Intern Med"},{"key":"737_CR25","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.18609\/cgti.2019.156","volume":"5","author":"E Fritsche","year":"2019","unstructured":"Fritsche E, Elsallab M, Schaden M, Hey SP, Abou-El-Enein M. Post-marketing safety and efficacy surveillance of cell and gene therapies in the EU: a critical review. Cell Gene Ther Insights. 2019;5:1505\u201321. https:\/\/doi.org\/10.18609\/cgti.2019.156.","journal-title":"Cell Gene Ther Insights"},{"key":"737_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1236462","author":"L Burns","year":"2023","unstructured":"Burns L, Le Roux N, Kalesnik-Orszulak R, Christian J, Dudinak J, Rockhold F, et al. Real-world evidence for regulatory decision-making: updated guidance from around the world. Front Med. 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1236462.","journal-title":"Front Med"},{"key":"737_CR27","unstructured":"European Medicines Agency. Post-authorisation measures: questions and answers n.d. https:\/\/www.ema.europa.eu\/en\/pharmacovigilance-post-authorisation\/post-authorisation-measures-questions-and-answers. Accessed 14 Feb 2025."},{"key":"737_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cpt.2461","volume":"111","author":"R Flynn","year":"2022","unstructured":"Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven RG, Gordillo-Mara\u00f1on M, et al. Marketing authorization applications made to the European Medicines Agency in 2018\u20132019: what was the contribution of real-world evidence? Clin Pharmacol Ther. 2022;111:90\u20137. https:\/\/doi.org\/10.1002\/cpt.2461.","journal-title":"Clin Pharmacol Ther"},{"key":"737_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.1426","volume":"106","author":"A Cave","year":"2019","unstructured":"Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106:36\u20139. https:\/\/doi.org\/10.1002\/cpt.1426.","journal-title":"Clin Pharmacol Ther"},{"key":"737_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01528-7","author":"F Windfuhr","year":"2025","unstructured":"Windfuhr F, de Vries ST, Melinder M, Dahlqvist T, Almeida D, Sepodes B, et al. Stakeholders\u2019 perspectives toward the use of patient registry data for decision-making on medicines: a cross-sectional survey. Drug Saf. 2025. https:\/\/doi.org\/10.1007\/s40264-025-01528-7.","journal-title":"Drug Saf"},{"key":"737_CR31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40264-019-00848-9","volume":"42","author":"P McGettigan","year":"2019","unstructured":"McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, et al. Patient registries: an underused resource for medicines evaluation. Drug Saf. 2019;42:1343\u201351. https:\/\/doi.org\/10.1007\/s40264-019-00848-9.","journal-title":"Drug Saf"},{"key":"737_CR32","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/pds.4196","volume":"26","author":"JC Bouvy","year":"2017","unstructured":"Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005\u20132013. Pharmacoepidemiol Drug Saf. 2017;26:1442\u201350. https:\/\/doi.org\/10.1002\/pds.4196.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"737_CR33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/pds.4449","volume":"27","author":"A Pacurariu","year":"2018","unstructured":"Pacurariu A, Plueschke K, Olmo CA, Kurz X. Imposed registries within the European postmarketing surveillance system: extended analysis and lessons learned for regulators. Pharmacoepidemiol Drug Saf. 2018;27:823\u20136. https:\/\/doi.org\/10.1002\/pds.4449.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"737_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1214766","author":"R Raycheva","year":"2023","unstructured":"Raycheva R, Kostadinov K, Mitova E, Bogoeva N, Iskrov G, Stefanov G, et al. Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1214766.","journal-title":"Front Public Health"},{"key":"737_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209743","author":"DH Schoenmakers","year":"2024","unstructured":"Schoenmakers DH, Van Den Berg S, Timmers L, Adang LA, B\u00e4umer T, Bosch A, et al. Framework for multistakeholder patient registries in the field of rare diseases: focus on neurogenetic diseases. Neurology. 2024. https:\/\/doi.org\/10.1212\/WNL.0000000000209743.","journal-title":"Neurology"},{"key":"737_CR36","unstructured":"European Medicines Agency. HMA-EMA Catalogues of RWD sources: the World Federation of Hemophilia Gene Therapy Registry n.d. https:\/\/catalogues.ema.europa.eu\/node\/1018\/administrative-details. Accessed 14 Feb 2025."},{"key":"737_CR37","unstructured":"European Medicines Agency. HMA-EMA Catalogues of RWD sources: European Society for Blood and Marrow Transplantation (EBMT) n.d. https:\/\/catalogues.ema.europa.eu\/institution\/1000000016. Accessed 14 Feb 2025."},{"key":"737_CR38","unstructured":"European Medicines Agency. HMA-EMA Catalogues of RWD sources: Center for International Blood and Marrow Transplant Research (CIBMTR) n.d. https:\/\/catalogues.ema.europa.eu\/institution\/3331384. Accessed 14 Feb 2025."},{"key":"737_CR39","unstructured":"European Medicines Agency. HMA-EMA Catalogues of RWD sources: American Thrombosis and Hemostasis Network (ATHN) n.d. https:\/\/catalogues.ema.europa.eu\/institution\/3331405. Accessed 14 Feb 2025."},{"key":"737_CR40","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) qualification opinion on cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt-registry_en.pdf. Accessed 29 Feb 2025."},{"key":"737_CR41","unstructured":"European Medicines Agency. Letter of Support for World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/letter-support-world-federation-hemophilia-wfh-gene-therapy-registry-gtr_en.pdf. Accessed 29 Feb 2025."},{"key":"737_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jval.2022.04.1738","volume":"26","author":"EM Oehrlein","year":"2023","unstructured":"Oehrlein EM, Schoch S, Burcu M, McBeth JF, Bright J, Pashos CL, et al. Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process. Value Health. 2023;26:28\u201338. https:\/\/doi.org\/10.1016\/j.jval.2022.04.1738.","journal-title":"Value Health"},{"key":"737_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1408636","author":"D Almeida","year":"2024","unstructured":"Almeida D, Umuhire D, Gonzalez-Quevedo R, Ant\u00f3nio A, Burgos JG, Verpillat P, et al. Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU. Front Med (Lausanne). 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1408636.","journal-title":"Front Med (Lausanne)"},{"key":"737_CR44","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/bcp.13165","volume":"83","author":"P Engel","year":"2017","unstructured":"Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer NA. Lessons learned on the design and the conduct of post-authorization safety studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol. 2017;83:884\u201393. https:\/\/doi.org\/10.1111\/bcp.13165.","journal-title":"Br J Clin Pharmacol"},{"key":"737_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jval.2023.10.007","volume":"27","author":"FD Mowlem","year":"2023","unstructured":"Mowlem FD, Elash CA, Dumais KM, Haenel E, O\u2019Donohoe P, Olt J, et al. Best practices for the electronic implementation and migration of patient-reported outcome measures. Value Health. 2023;27:79\u201394. https:\/\/doi.org\/10.1016\/j.jval.2023.10.007.","journal-title":"Value Health"},{"key":"737_CR46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12913-022-07657-4","volume":"22","author":"R Ruseckaite","year":"2022","unstructured":"Ruseckaite R, Maharaj AD, Dean J, Krysinska K, Ackerman IN, Brennan AL, et al. Preliminary development of recommendations for the inclusion of patient-reported outcome measures in clinical quality registries. BMC Health Serv Res. 2022;22:276. https:\/\/doi.org\/10.1186\/s12913-022-07657-4.","journal-title":"BMC Health Serv Res"},{"key":"737_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s41687-022-00466-7","volume":"6","author":"K Maruszczyk","year":"2022","unstructured":"Maruszczyk K, Aiyegbusi OL, Torlinska B, Collis P, Keeley T, Calvert MJ. Systematic review of guidance for the collection and use of patient-reported outcomes in real-world evidence generation to support regulation, reimbursement and health policy. J Patient Rep Outcomes. 2022;6:57. https:\/\/doi.org\/10.1186\/s41687-022-00466-7.","journal-title":"J Patient Rep Outcomes"},{"key":"737_CR48","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1111\/jth.15023","volume":"18","author":"B Konkle","year":"2020","unstructured":"Konkle B, Pierce G, Coffin D, Naccache M, Clark RC, George L, et al. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH. J Thromb Haemost. 2020;18:3074\u20137. https:\/\/doi.org\/10.1111\/jth.15023.","journal-title":"J Thromb Haemost"},{"key":"737_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13:61. https:\/\/doi.org\/10.1186\/s13023-018-0810-x.","journal-title":"Orphanet J Rare Dis"},{"key":"737_CR50","unstructured":"European Parliament and Council. Proposal for a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending regulation (EC) no. 1394\/2007 and regulation (EU) no. 536\/2014 and repealing regulation (EC) no. 726\/2004, Regulation (EC) No 141\/2000 and regulation (EC) no. 1901\/2006. 2023. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52023PC0193. Accessed 15 Mar 2025."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00737-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:26:33Z","timestamp":1761704793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00737-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00737-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"22 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by FCT|FCCN (b-on). This project has received funding from the European Union\u2019s Horizon Europe Research and Innovation Actions under grant no. 101095479 (More-EUROPA). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union nor the granting authority. Neither the European Union nor the granting authority can be held responsible for them.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"D.M. is employed by Infosa\u00fade-Instituto de Forma\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, but all research was conducted at Faculdade de Farm\u00e1cia, Universidade de Lisboa.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data analysed during this study are included in this published article and its supplementary information file.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to this research according to the International Committee of Medical Journal Editors (ICMJE) criteria to qualify as a listed author. B.S. and C.T. contributed to the conceptualisation and formulation of the research question. D.A., D.M. and C.T. performed data collection. D.A. drafted the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency\/agencies or organisations with which the author(s) is\/are employed\/affiliated.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}